Sound Bioventures, a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and the USA developing specialty therapeutics, announced that Fredrik Lehmann, Ph.D., MBA, joined the company as its first Entrepreneur-in-Residence.
Lehmann will lead efforts to identify promising clinical, or soon to be clinical candidate drugs from academic or industry sources (where they are considered to be non-core) and create new companies around them, providing capital, development expertise, and access to additional resources within our extensive network.
Before joining Sound Bioventures, he was a venture partner at Swedish venture capital fund Industrifonden. Prior to this, Lehmann worked in a variety of biotech industry executive and operational roles including as CEO, Head of Research and CMC Director for several biotech companies, including Oncopeptides (as Head of Research and CMC), Recipharm (General Manager) and EpiEndo (CEO and CMC Director). He also founded several life science companies, including OT Chemistry, which was acquired by Recipharm in 2015.
Lehmann gained his Ph.D. from Göteborg University and an executive MBA from Stockholm School of Economics. He has published over 50 peer-reviewed articles and been responsible for more than 25 international patent applications.
Sound Bioventures is a specialist life sciences venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and the USA developing specialty therapeutics in areas of significant clinical unmet need.
The founding team has an active, hands-on approach and brings considerable operational and VC investment experience, including working together on over 40 investments over the past 15 years.
Sound Bioventures operates from key locations in Copenhagen (Denmark), Stockholm (Sweden) and Washington DC (USA).